{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-23-000006","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.534781+00:00","generated_at":"2026-06-19T20:14:58.280353+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbbVie reports FY 2022 adjusted EPS $13.77 (+16.4% YoY); guides FY 2023 adjusted EPS $10.70-$11.10","bullets":["FY 2022 net revenues $58.054B (+3.3% reported, +5.1% operational); Q4 net revenues $15.121B (+1.6% reported, +3.8% operational).","GAAP diluted EPS FY $6.63 (+2.8%); adjusted diluted EPS $13.77 (+16.4%). Q4 GAAP diluted EPS $1.38 (-38.9%); adjusted $3.60 (+16.9%).","Immunology portfolio FY net revenues $28.924B (+14.4%); Humira $21.237B, Skyrizi $5.165B, Rinvoq $2.522B.","Hematologic oncology portfolio FY net revenues $6.577B (-9.0%); Imbruvica $4.568B, Venclexta $2.009B.","2023 adjusted diluted EPS guidance $10.70-$11.10 (excludes IPR&D and milestones); management cites U.S. Humira LOE as headwind."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-23-000006","json":"https://secwatch.observer/filing/0001551152-23-000006.json","markdown":"https://secwatch.observer/filing/0001551152-23-000006.md","text":"https://secwatch.observer/filing/0001551152-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000006/0001551152-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000006/abbv-20230209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T20:14:58.280353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc5ea9b4754ae0d0599c3b6d22e1ee08f3d18e2b","claim":"AbbVie Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On February 9, 2023, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000006/0001551152-23-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}